Scholarlink

Objectives <p>In patients with juvenile idiopathic arthritis (JIA), the approach to discontinuing biological treatments after a period of remission remains exploratory. We aimed to identify one or more predictors of relapse after the discontinuation of biologic/targeted synthetic disease-modifying anti-rheumatic drugs.</p> Methods <p>We reviewed JIA patients followed in two French tertiary centers and included in the JIR cohort who had discontinued their biologic treatments from 2000 to 2023. Remission was defined according to the Wallace criteria. The primary outcome was relapse within 1 year after treatment withdrawal. Multivariate regression was used to analyze predictors of relapse.</p> Results <p>A total of 697 JIA patients received treatment in the two centers during the study period. We analyzed 130 instances of treatment discontinuation in 115 patients (16.5%) (70.8% girls [92/130], median age 5.29 years at diagnosis [interquartile range 2.3–10.4]). Patients discontinued biological treatments after a median of 2.58 years, and 56.2% (73/130) of patients experienced relapse within 1 year after treatment withdrawal. The psoriasis subgroup had the highest relapse rate (89.5% [17/19]) and the systemic subgroup the lowest (33.3% [7/21]). The probably of relapse was increased with antinuclear antibody positivity at diagnosis (<i>p</i> &lt; 0.05) and reduced with longer duration of clinically inactive disease before treatment withdrawal.</p> Conclusion <p>Relapses are common after discontinuing biologic therapies in JIA, particularly in patients with antinuclear antibody positivity and psoriatic arthritis and those who stop treatment shortly after reaching inactive disease status.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors of relapse after withdrawing biotherapies in children with inactive juvenile idiopathic arthritis: a retrospective cohort study of the JIR cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月20日

查看全文
  • Vincent Jallot,
  • Isabelle Koné-Paut,
  • Sébastien Cavelot,
  • Caroline Galeotti,
  • Linda Rossi-Semerano,
  • Véronique Hentgen,
  • Perrine Dusser

摘要

Objectives

In patients with juvenile idiopathic arthritis (JIA), the approach to discontinuing biological treatments after a period of remission remains exploratory. We aimed to identify one or more predictors of relapse after the discontinuation of biologic/targeted synthetic disease-modifying anti-rheumatic drugs.

Methods

We reviewed JIA patients followed in two French tertiary centers and included in the JIR cohort who had discontinued their biologic treatments from 2000 to 2023. Remission was defined according to the Wallace criteria. The primary outcome was relapse within 1 year after treatment withdrawal. Multivariate regression was used to analyze predictors of relapse.

Results

A total of 697 JIA patients received treatment in the two centers during the study period. We analyzed 130 instances of treatment discontinuation in 115 patients (16.5%) (70.8% girls [92/130], median age 5.29 years at diagnosis [interquartile range 2.3–10.4]). Patients discontinued biological treatments after a median of 2.58 years, and 56.2% (73/130) of patients experienced relapse within 1 year after treatment withdrawal. The psoriasis subgroup had the highest relapse rate (89.5% [17/19]) and the systemic subgroup the lowest (33.3% [7/21]). The probably of relapse was increased with antinuclear antibody positivity at diagnosis (p < 0.05) and reduced with longer duration of clinically inactive disease before treatment withdrawal.

Conclusion

Relapses are common after discontinuing biologic therapies in JIA, particularly in patients with antinuclear antibody positivity and psoriatic arthritis and those who stop treatment shortly after reaching inactive disease status.